Meanwhile, the company continues to see growth among its offerings with lower reimbursement risk.
Myriad RBM has manufactured and validated immunoassays based on Quanterix's single molecule array technology, Simoa.
CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.
NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements.
The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014.
In Science this week: gene regulation changes linked to human brain evolution, and more.
The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.
Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.
A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.